SynthesisClinical rheumatology2019

Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials.

Yanrong Huang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.